Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance

Novartis27 enrolled

Overview

THE PURPOSE OF THIS STUDY IS TO DETERMINE IF 24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG) IMPROVES INSULIN SENSITIVITY IN SUBJECTS WITH HIGHER THAN NORMAL GLUCOSE LEVELS USING A TEST CALLED THE EUGLYCEMIC CLAMP.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypertension Impaired Glucose Tolerance

Interventions

valsartanDRUG

24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: history or presenting hypertension Elevated fasting blood glucose levels - Exclusion Criteria: Pregnancy potential Diabetes mellitus Other criteria apply \-

Outcomes

Primary Outcomes

Change from baseline insulin sensitivity after 24 weeks

Secondary Outcomes

Change from baseline in the function of cells that line blood vessels after 24 weeks

Change from baseline in markers of vascular inflammation after 24 weeks

Adverse events and serious adverse events at each study visit for 24 weeks

Hematology, blood chemistries, and urine measurements for up to 24 weeks

Vital signs and physical examinations for up to 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.